ArticleHaematologica2016
Interleukin-15-activated cytokine-induced killer cells may sustain remission in leukemia patients after allogeneic stem cell transplantation: feasibility, safety and first insights on efficacy.
2 registry-linked trialsOpen access · goldAbstract readLetterMulticenter Study
In one paragraph
Article in Haematologica, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 25 papers.
0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
3.5field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
NCT03821519 phase1 / phase2unknown statusnot on this mapstarted 2019, after this paper: background citation
Phase I/II Trial of Donor Derived Cytokine Induced Killer (CIK) Cells Infusion for Relapsed Hematologic Malignancy After Haploidentical Stem Cell Transplantation
An Investigator's Initiated Clinical Study to Evaluate the Safety of Cytokine-Induced-Killer Cells During Early Transplant Period of Autologous Hematopoietic Stem Cell Transplant Recipients.
Who cites it
25 citing papers in PubMed, 42 citations in OpenAlex.
- First-in-Human Study of IL15-Activated Cytokine-Induced Killer Cells After Allogeneic HCT Shows Durable Remission and Serotherapy-Associated Immune Reconstitution in Leukemia.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026Trial
- Treatment of relapse after allogeneic stem cell transplantation in children and adolescents with ALL: the Frankfurt experience.Bone marrow transplantation · 2017Trial
- Therapeutic Potential of CAR-CIK Cells in Acute Leukemia Relapsed Post Allogeneic Stem Cell Transplantation.Cancers · 2025Review
- Cytokine-Induced Killer Cells: A Unique Platform for Adoptive Cell Immunotherapy after Allogeneic Hematopoietic Stem Cell Transplantation.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2025Review
- CAR-CIK vs. CAR-T: benchmarking novel cytokine-induced killer cells as solid tumor immunotherapy in ErbB2+ rhabdomyosarcoma.Frontiers in immunology · 2025Article
- Cytokine-induced killer cells: new insights for therapy of hematologic malignancies.Stem cell research & therapy · 2024Review
- Review
- Genetically modified and unmodified cellular approaches to enhance graft versus leukemia effect, without increasing graft versus host disease: the use of allogeneic cytokine-induced killer cells.Frontiers in immunology · 2024Review
- How can Cytokine-induced killer cells overcome CAR-T cell limits.Frontiers in immunology · 2023Review
- The Hematology of Tomorrow Is Here-Preclinical Models Are Not: Cell Therapy for Hematological Malignancies.Cancers · 2022Review
- The Role of Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Leukemia.Journal of clinical medicine · 2021Review
- Association of IL-15 and IP-10 Serum Levels with Cytomegalovirus Infection, CMV Viral Load and Cyclosporine Level after Kidney Transplantation.Reports of biochemistry & molecular biology · 2021Article
- Arming Immune Cells for Battle: A Brief Journey through the Advancements of T and NK Cell Immunotherapy.Cancers · 2021Review
- Bispecific Antibodies and Other Non-CAR Targeted Therapies and HSCT: Decreased Toxicity for Better Transplant Outcome in Paediatric ALL?Frontiers in pediatrics · 2021Review
- Novel Immune Cell-Based Therapies to Eradicate High-Risk Acute Myeloid Leukemia.Frontiers in immunology · 2021Review
- NKG2D Engagement Alone Is Sufficient to Activate Cytokine-Induced Killer Cells While 2B4 Only Provides Limited Coactivation.Frontiers in immunology · 2021Article
- Cell-based and antibody-mediated immunotherapies directed against leukemic stem cells in acute myeloid leukemia: Perspectives and open issues.Stem cells translational medicine · 2020Review
- Immunotherapy-Based Targeting and Elimination of Leukemic Stem Cells in AML and CML.International journal of molecular sciences · 2019Review
- Ex vivo expansion of autologous, donor-derived NK-, γδT-, and cytokine induced killer (CIK) cells post haploidentical hematopoietic stem cell transplantation results in increased antitumor activity.Bone marrow transplantation · 2019Article
- Improving Clinical Manufacturing of IL-15 Activated Cytokine-Induced Killer (CIK) Cells.Frontiers in immunology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 2 countries.
Eva RettingerJW Goethe University Frankfurt, Hospital for Children and Adolescents, Department of Stem Cell Transplantation and Immunology, Germany eva.rettinger@kgu.de peter.bader@kgu.de.
Sabine HueneckeJW Goethe University Frankfurt, Hospital for Children and Adolescents, Department of Stem Cell Transplantation and Immunology, Germany.
Halvard BonigJW Goethe University Frankfurt, Institute for Transfusion Medicine and Immunohematology, and German Red Cross Blood Donor Service Baden-Württemberg-Hessen, Department of Cellular Therapeutics / Cell Processing (GMP), Frankfurt/Main, Germany University of Washington, Department of Medicine/Hematology, Seattle, WA, USA.
Michael MerkerJW Goethe University Frankfurt, Hospital for Children and Adolescents, Department of Stem Cell Transplantation and Immunology, Germany.
Andrea JarischJW Goethe University Frankfurt, Hospital for Children and Adolescents, Department of Stem Cell Transplantation and Immunology, Germany.
Jan SoerensenJW Goethe University Frankfurt, Hospital for Children and Adolescents, Department of Stem Cell Transplantation and Immunology, Germany.
Andre WillaschJW Goethe University Frankfurt, Hospital for Children and Adolescents, Department of Stem Cell Transplantation and Immunology, Germany.
Gesine BugJW Goethe University Frankfurt, Department of Medicine II, Hematology, Oncology, Rheumatology and Infectious Diseases, Germany.
Ansgar SchulzUniversity Medical Center Ulm, Department of Pediatrics, Germany.
Thomas KlingebielJW Goethe University Frankfurt, Hospital for Children and Adolescents, Department of Stem Cell Transplantation and Immunology, Germany.
Peter BaderJW Goethe University Frankfurt, Hospital for Children and Adolescents, Department of Stem Cell Transplantation and Immunology, Germany eva.rettinger@kgu.de peter.bader@kgu.de.
Goethe University Frankfurt · DEGerman Red Cross · DE
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Hematopoietic Stem Cell TransplantationAdolescentAdultAgedChildChild, PreschoolCytokine-Induced Killer CellsFemaleGraft vs Host DiseaseHaplotypesHistocompatibility TestingHumansInfantInterleukin-15Leukemia, Myelogenous, Chronic, BCR-ABL PositiveLeukemia, Myeloid, AcuteInterleukin-15cytokine-induced killer cellsefficacyHSCTIL-15-activatedimmunological controlrelapse
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT03821519ClinicalTrials.gov
NCT07692607ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.